New Research from the CWMH: Data on the Reproductive Safety of Vortioxetine
New prospective data on 56 first-trimester vortioxetine exposures found no major malformations, offering reassuring but still preliminary reproductive safety information.
New prospective data on 56 first-trimester vortioxetine exposures found no major malformations, offering reassuring but still preliminary reproductive safety information.
New registry data found no major malformations among 58 infants exposed to cariprazine in the first trimester, offering reassuring but preliminary reproductive safety evidence.
Dr. Marlene Freeman recently shared her insights on Psychiatric Medications and Considerations for Individuals Across Pregnancy, the Postpartum, and Reproductive Years with the National Alliance on Mental Illness on March 7, 2024.